SignalRx for Specialty Pharmacy

In specialty pharmacy, accreditation is the price of entry: payers and manufacturers require it, so an accredited provider and an unaccredited one are effectively in different markets, and that status is not visible on a website. Layer on ownership that runs from independents to health systems to payer-owned operations, and therapy focus that makes an oncology pharmacy a different account from a rare-disease one, and list building gets hard fast. SignalRx flags accreditation and therapy focus, resolves ownership, scores each account, and puts the result to work in Salesforce.

How the specialty pharmacy market is built

Specialty pharmacies dispense high-cost, complex therapies for conditions like oncology, autoimmune disease, and rare disease, where the drug is expensive, handling is demanding, and adherence support matters. They layer on hub services, patient support, and often infusion. Ownership varies widely, and accreditation is a defining feature because payers and manufacturers require it.

Subsegments that matter

• Independent specialty pharmacies, often therapy-focused and nimble.
• Health-system specialty pharmacies, built to keep prescriptions inside the system.
• PBM and payer-owned specialty pharmacies, large and centralized.
• Infusion providers, home and ambulatory, frequently overlapping with specialty.

Why selling into specialty pharmacy is hard

Accreditation gates the market, so an account without the right accreditation may not be a real prospect, and that status is not obvious from a website. Ownership varies, so an independent, a system pharmacy, and a payer-owned operation each buy differently. And therapy focus matters, so an oncology-focused pharmacy and a rare-disease one are effectively different accounts.

The data that identifies a specialty pharmacy account

NPPES lists pharmacies, their taxonomies, and locations. State boards of pharmacy, registered through NABP, publish licensing. Accreditation bodies such as URAC and ACHC publish accredited specialty and infusion pharmacies, a strong qualifier. Public ownership and corporate filings expose system and payer affiliation, and 340B contract pharmacy arrangements reveal covered-entity relationships. These anchor whether an account is even a real market and who owns it on paper.

Current ownership and the buyer, though, move faster than a filing. News and press coverage of PBM, payer, and health-system acquisitions of specialty and infusion pharmacies dates a change of hands as it happens. LinkedIn surfaces pharmacy leadership and the clinical-program buyers who actually evaluate a product. The pharmacy's own website confirms therapy focus and the hub services it runs. SignalRx pulls all of these in, matches them to your CRM on NPI, flags accreditation and therapy focus, and resolves ownership through triangulation, assigning a parent-to-child structure that rolls each pharmacy up to its owning health system, PBM, or payer. Where a pharmacy record is sparse, it fills the missing fields from these same public sources so the account becomes scoreable.

How SignalRx turns that data into Revenue Plays

SignalRx researches and tags the signals that qualify a specialty pharmacy account, then scores it on both the account and its contacts. Because most pharmacies on a prospecting list are net-new, the Fit Score is built from external public data, URAC and ACHC accreditation directories, NPPES, state boards via NABP, and ownership filings anchoring the account while acquisition news, LinkedIn, and the pharmacy website keep ownership and therapy focus current, while the Health Score and your own internal signal, revenue, support, and product-usage history tracked over time, come in once the pharmacy is a customer as the expansion layer. When an accreditation directory and your internal record disagree, SignalRx uses inference to decide which to trust rather than overwriting either. The resulting tags and scores are written into Revenue Plays and lists native to Salesforce, so a rep sees accreditation status, therapy focus, and the next action on the record.

Illustrative, based on how SignalRx customers work. A vendor loads a pharmacy list. SignalRx flags which accounts hold URAC or ACHC accreditation, tags each by therapy focus from directories and pharmacy websites, resolves the payer-owned and health-system parents and confirms one against a recent acquisition in the press, and routes an accredited oncology account already showing product usage into an expansion play.

Plays that work in specialty pharmacy

Build a net-new list of accredited, high-fit pharmacies in the therapy areas you serve. Prioritize inbound so an accredited, in-focus account outranks one that is neither. Segment by ownership and therapy so messaging matches. And once an operator buys, find expansion across its other sites and service lines.

Key takeaways

• Accreditation from URAC and ACHC defines the market and is a strong qualifier.
• Ownership and therapy focus make accounts behave like separate markets.
• NPPES, state boards via NABP, and accreditation directories identify and qualify accounts, while acquisition news, LinkedIn, and the pharmacy website keep ownership and therapy focus current.
• Tags and scores across external and internal data land in Salesforce plays and lists ready to work.

See it in action: Discover High-Fit Prospects with SignalRx.

Related: Build a target account list, Prioritize inbound leads by fit, Segment your customers, Find expansion opportunities.